MetaADEDB 2.0 @ LMMD
Hydroxocobalamin
(DQOCFCZRZOAIBN-WZHZPDAFSA-L)
Structure
SMILES
OC[C@H]1O[C@@H]([C@@H]([C@@H]1OP(=O)(O[C@@H](CNC(=O)CC[C@@]1(C)/C/2=C(\C)/C3=N/C(=C\C4=N/C(=C(\C5=N[C@]([C@@H]([C@@H]1CC(=O)N)[N-]2)(C)[C@@](C)(CC(=O)N)[C@@H]5CCC(=O)N)/C)/[C@@]([C@@H]4CCC(=O)N)(C)CC(=O)N)/C([C@@H]3CCC(=O)N)(C)C)C)[O-])O)n1cnc2c1cc(C)c(c2)C.O.[Co+2]
Molecular Formula:
C62H90CoN13O15P
Molecular Weight:
1347.360
Log P:
6.5512
Hydrogen Bond Acceptor:
27
Hydrogen Bond Donor:
10
TPSA:
469.86
CAS Number(s):
13422-51-0
Synonym(s)
1.
Hydroxocobalamin
2.
Hydroxycobalamin
3.
Hydroxo-Cobalamin
External Link(s)
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal discomfortSIDER
2Abdominal sepsisOFFSIDES
3Acute myocardial infarctionOFFSIDES
4Acute respiratory failureOFFSIDES
5AgitationSIDER
6Anaphylactic shockSIDER
7AngioedemaSIDER
8AnhidrosisOFFSIDES
9AnorexiaOFFSIDES
10ApathyOFFSIDES
11Aphthous StomatitisOFFSIDES
12Arteriovenous graft thrombosisOFFSIDES
13Autoimmune thrombocytopeniaOFFSIDES
14Blood amylase increasedOFFSIDES
15Blood and lymphatic system disordersSIDER
16Blood creatine phosphokinase increasedOFFSIDES
17Blood prolactin increasedOFFSIDES
18Brain DeathOFFSIDES
19Bullous eruptionSIDER
20Cardiac ArrestSIDER
21Cardiac ventricular disorderOFFSIDES
22Cerebral atrophyOFFSIDES
23CheilitisOFFSIDES
24Chest PainSIDER
25Chest discomfortSIDER
26ChillsSIDER
27Choking sensationOFFSIDES
28ChromaturiaSIDER
29ConfabulationOFFSIDES
30DehydrationOFFSIDES
31DermatitisSIDER
32Device FailureOFFSIDES
33DiscomfortSIDER
34DiverticulitisOFFSIDES
35DizzinessSIDER
36Duodenal ulcer perforationOFFSIDES
37DyspepsiaSIDER
38EczemaSIDER
39Electrocardiogram repolarisation abnormalitySIDER
40EpistaxisOFFSIDES
41ErythemaOFFSIDES
SIDER
42Escherichia infectionOFFSIDES
43Escherichia urinary tract infectionOFFSIDES
44FatigueOFFSIDES
45Feeling abnormalSIDER
46Fluid imbalanceOFFSIDES
47FolliculitisSIDER
48Gastrointestinal toxicityOFFSIDES
49General disorders and administration site conditionsSIDER
50Head BangingOFFSIDES
51HeadacheSIDER
52Hip surgeryOFFSIDES
53HypersensitivitySIDER
54Hypoaesthesia facialOFFSIDES
55Incorrect dose administeredOFFSIDES
56Infusion site erythemaOFFSIDES
57Infusion site infectionOFFSIDES
58Infusion site inflammationOFFSIDES
59Infusion site massOFFSIDES
60Infusion site painOFFSIDES
61Infusion site reactionSIDER
62Injection Site ReactionSIDER
63MalaiseSIDER
64Memory impairmentSIDER
65Mental impairmentOFFSIDES
66Muscle WeaknessOFFSIDES
67NauseaSIDER
68Neutropenic sepsisOFFSIDES
69PainOFFSIDES
SIDER
70PallorOFFSIDES
71PancreatitisOFFSIDES
72PruritusSIDER
73RednessSIDER
74Sinus operationOFFSIDES
75SwellingSIDER
76TachycardiaSIDER
77ThrombosisSIDER
78Urinary tract infection enterococcalOFFSIDES
79UrticariaSIDER
80VIIth nerve paralysisOFFSIDES
81Vascular Access ComplicationOFFSIDES
82nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.